 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...169170171172173174175176177178179...235236» |
- | Trial completion date, Metastases: PRODIGE 37-FIRGEMAX: FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine (clinicaltrials.gov) - Jun 21, 2019
P2, N=127, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial completion date: Nov 2018 --> Dec 2019
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer (clinicaltrials.gov) - Jun 21, 2019
P=N/A, N=25, Completed, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Trial completion date: Nov 2018 --> Dec 2019 Recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019 | Trial primary completion date: Sep 2019 --> Apr 2019
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment change, Combination therapy: NEO-Nal- IRI: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 21, 2019
P2, N=53, Recruiting, Sponsor: University of Florida
Recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019 | Trial primary completion date: Sep 2019 --> Apr 2019 N=28 --> 53
- | leucovorin calcium / generics, fluorouracil / generics, cyclophosphamide intravenous / generics
Journal: Postmenopausal choriocarcinoma: a rare case report and review of the literature. (Pubmed Central) - Jun 20, 2019
N=28 --> 53 This patient has shown a mild response to chemotherapy when compared with patients in reproductive age, and the combination of standard chemotherapy with local injection chemotherapy may be helpful for treating similar clinical cases.
- | Trial completion date, Metastases: PRODIGE 35-PANOPTIMOX: First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem (clinicaltrials.gov) - Jun 20, 2019
P2, N=276, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
This patient has shown a mild response to chemotherapy when compared with patients in reproductive age, and the combination of standard chemotherapy with local injection chemotherapy may be helpful for treating similar clinical cases. Trial completion date: Feb 2019 --> Dec 2019
- | Jakafi (ruxolitinib) / Incyte
Enrollment closed, Enrollment change: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 20, 2019
P2, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Feb 2019 --> Dec 2019 Recruiting --> Active, not recruiting | N=92 --> 12
- | Enrollment open: NRG-GI006: Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (clinicaltrials.gov) - Jun 20, 2019
P3, N=300, Recruiting, Sponsor: NRG Oncology
Recruiting --> Active, not recruiting | N=92 --> 12 Not yet recruiting --> Recruiting
- | Trial completion date, Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 19, 2019
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Jan 2020 | Trial primary completion date: Dec 2018 --> Jul 2019
- | Trial completion, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Jun 19, 2019
P2/3, N=716, Completed, Sponsor: Krankenhaus Nordwest
Trial completion date: Dec 2018 --> Jan 2020 | Trial primary completion date: Dec 2018 --> Jul 2019 Active, not recruiting --> Completed
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Enrollment open, Metastases: NCI-2018-02122: Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin (clinicaltrials.gov) - Jun 19, 2019
P2, N=37, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Abraxane (albumin-bound paclitaxel) / Celgene, Otsuka
Clinical, Review, Journal, HEOR, Real-World Evidence: Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. (Pubmed Central) - Jun 18, 2019
Therefore, a randomized, controlled trial is warranted. Toxicity profile differences represent key considerations for treatment decisions.
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Jun 17, 2019
P2, N=17, Active, not recruiting, Sponsor: University of Southern California
Toxicity profile differences represent key considerations for treatment decisions. Trial primary completion date: Aug 2019 --> Dec 2019
- || epacadostat (INCB024360) / Incyte
Trial primary completion date, Metastases: A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) (clinicaltrials.gov) - Jun 17, 2019
P1/2, N=70, Active, not recruiting, Sponsor: Incyte Corporation
Trial primary completion date: Aug 2019 --> Dec 2019 Trial primary completion date: Oct 2019 --> Jan 2019
- | leucovorin calcium / generics
Journal: Folate deficiency prevents neural crest fate by disturbing the epigenetic Sox2 repression on the dorsal neural tube. (Pubmed Central) - Jun 17, 2019
By using bisulfite sequencing, we show that this phenotype is consequence of reduced DNA methylation on the Sox2 locus at the dorsal neural tube, which can be rescued by the addition of folinic acid. Taken together, our in vivo results reveal the importance of folate as a source of the methyl groups necessary for the establishment of the correct epigenetic marks during neural and neural crest fate-restriction.
- | Trial completion date, Metastases: LAPC-1: Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer. (clinicaltrials.gov) - Jun 17, 2019
P=N/A, N=53, Active, not recruiting, Sponsor: Foundation for Liver Research
Taken together, our in vivo results reveal the importance of folate as a source of the methyl groups necessary for the establishment of the correct epigenetic marks during neural and neural crest fate-restriction. Trial completion date: Nov 2020 --> Nov 2019
- | leucovorin calcium / generics
Clinical, Journal: Short-term folinic acid supplementation and aerobic exercise improve vascular reactivity in HIV-infected individuals. (Pubmed Central) - Jun 15, 2019
Results demonstrate that supervised exercise and folinic acid supplementation in very short term improve endothelial function in HIV-infected individuals. As exercise and folate supplementation are safe and relatively inexpensive, this finding deserves more attention in large randomized clinical trials in an attempt to reduce cardiovascular risk in HIV-infected population.
- | Avastin (bevacizumab) / Roche
Journal: Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy. (Pubmed Central) - Jun 15, 2019
CPT-11 and SN-38 are detected in sweat released during intravenous CPT-11 administration. Beads of sweat or linen clothes that absorb the sweat might be the source of CPT-11 and SN-38 exposure.
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron
Clinical, Journal: AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. (Pubmed Central) - Jun 15, 2019
P2
The FOLFIRI + aflibercept regimen is active and tolerable; however, it failed to improve historical benchmarks of efficacy in chemonaive patients with mCRC. Preliminary data hint that this regimen has cytoreductive activity in disease with adverse biology.
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. (Pubmed Central) - Jun 15, 2019
Preliminary data hint that this regimen has cytoreductive activity in disease with adverse biology. The addition of SIRT for patients with RSP tumors, but not for those with LSP tumors, was associated with a statistically and clinically significant OS gain.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. (Pubmed Central) - Jun 15, 2019
These markers also helped assess cetuximab resistance and served as early predictors of initial treatment effectiveness. Furthermore, a simultaneous increase or decrease in the levels of both indicators was consistent with the observed differences in PFS.
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: Colonic mucinous adenocarcinoma causing intussusception and distant metastasis: A case report. (Pubmed Central) - Jun 14, 2019
Furthermore, a simultaneous increase or decrease in the levels of both indicators was consistent with the observed differences in PFS. Even though the prognosis of colonic MAC is poor, being able to receive timely surgical treatment, good nutritional status and reasonable postoperative chemotherapy are the key factors to prolonging patient's survival.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Clinical, Journal: Adjuvant Chemotherapy of Locally Advanced Colon Cancer: Final Results of a Randomized Trial Comparing 5-Fluorouracil and Folinic Acid with Folfiri. (Pubmed Central) - Jun 14, 2019
Besides tumor grading and sub-staging, prognosis of CC may depend on tumor location. Left-sided tumors had a significantly better prognosis irrespective of treatment.
- | Cyramza (ramucirumab) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy: FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (clinicaltrials.gov) - Jun 14, 2019
P2/3, N=908, Recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Left-sided tumors had a significantly better prognosis irrespective of treatment. Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Apr 2019 --> Apr 2020
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: NAPAN: Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer (clinicaltrials.gov) - Jun 13, 2019
P2, N=122, Not yet recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal, Cancer stem cells: Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy. (Pubmed Central) - Jun 13, 2019
In multivariate analyses, ABCG2 was an independent prognostic factor for OS [hazard ratio (HR)=2.877; P=0.046], and ABCC2 and SOX2 were independent prognostic factors for DFS (HR=2.831; P=0.014; HR=2.558, P=0.020, respectively). ABCC2, ABCG2 and SOX2 may be promising prognostic markers for patients with CC receiving FOLFOX-4 therapy.
- || dalutrafusp alfa (AGEN1423) / Agenus
Enrollment open, Combination therapy, Monotherapy, Metastases: Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 12, 2019
P1, N=33, Recruiting, Sponsor: Gilead Sciences
ABCC2, ABCG2 and SOX2 may be promising prognostic markers for patients with CC receiving FOLFOX-4 therapy. Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Surgery, Metastases: PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (clinicaltrials.gov) - Jun 12, 2019
P2/3, N=1194, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2021 --> Dec 2021
- | Avastin (bevacizumab) / Roche, NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial termination: Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis (clinicaltrials.gov) - Jun 12, 2019
P2, N=2, Terminated, Sponsor: University of California, San Diego
Trial primary completion date: Jan 2021 --> Dec 2021 N=50 --> 2 | Trial completion date: Dec 2020 --> Apr 2019 | Active, not recruiting --> Terminated; unable to accrue
- |||||||||| otilimab (GSK3196165) / GSK
New P3 trial, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jun 11, 2019
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial: ISILI: Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (clinicaltrials.gov) - Jun 11, 2019
P1, N=75, Active, not recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- | leucovorin calcium / generics, fluorouracil / generics, doxorubicin hydrochloride / generics
Journal: Electroneutral polymersomes for combined cancer chemotherapy. (Pubmed Central) - Jun 9, 2019
This is the first time this particular polymersome has been used to encapsulate these three compounds with both an in-vitro and in-vivo evaluation carried out. This work will be of interest to those in the field of combination therapy, drug delivery, drug toxicity, multidrug resistance, liposomes, DDS and polymersomes.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Journal: Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. (Pubmed Central) - Jun 7, 2019
Electrolyte concentrations can hinder or improve drug electro-transport. Overall, balancing electrolyte concentration is needed for optimal electro-transport.
- | leucovorin calcium / generics, fluorouracil / generics
Retrospective data, Journal: Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study. (Pubmed Central) - Jun 6, 2019
T4 tumor and obstruction were independent poor prognostic factors affecting OS and DFS. In our population, the improvement of OS and DFS with ACT was not statistically significant in high-risk and low-risk patients with Stage II CRC.
- | New P2 trial: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 5, 2019
P2, N=45, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | leucovorin calcium / generics, fluorouracil / generics
Biomarker, Journal: Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. (Pubmed Central) - Jun 5, 2019
DPD tumour expression was a negative prognostic biomarker. Together with tumour expression of hENT1, DPD tumour expression defined patient subgroups that might benefit from either postoperative 5FU/FA or gemcitabine.
- | leucovorin calcium / generics, fluorouracil / generics
Biomarker, Clinical, Journal: Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. (Pubmed Central) - Jun 5, 2019
Together with tumour expression of hENT1, DPD tumour expression defined patient subgroups that might benefit from either postoperative 5FU/FA or gemcitabine. Expression of either DCTD or RRM1 was not prognostic or predictive in patients with pancreatic adenocarcinoma who had had post-operative chemotherapy with either gemcitabine or 5-fluorouracil with folinic acid.
- | veliparib (ABT-888) / AbbVie
Clinical, P1 data, Journal: A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. (Pubmed Central) - Jun 5, 2019
Expression of either DCTD or RRM1 was not prognostic or predictive in patients with pancreatic adenocarcinoma who had had post-operative chemotherapy with either gemcitabine or 5-fluorouracil with folinic acid. The acceptable safety profile and preliminary antitumour activity of veliparib plus FOLFIRI support further evaluation of this combination.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. (Pubmed Central) - Jun 5, 2019
When associated with triplet chemotherapy, bevacizumab induces a higher histopathologic response rate than cetuximab. The assessment of HGPs should be further explored as a predictor of benefit from available targeted agents.
- | Clinical, P2/3 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (Pubmed Central) - Jun 5, 2019
P2/3
The assessment of HGPs should be further explored as a predictor of benefit from available targeted agents. In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared with perioperative ECF/ECX.
- | Trial completion date, Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jun 5, 2019
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared with perioperative ECF/ECX. Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P3 trial, Metastases: Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jun 4, 2019
P3, N=933, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- | Enrollment change, Trial withdrawal, Metastases: Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 4, 2019
P2/3, N=0, Withdrawn, Sponsor: Guangxi Medical University
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 N=134 --> 0 | Active, not recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal, Metastases: Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 4, 2019
P2/3, N=0, Withdrawn, Sponsor: Guangxi Medical University
N=134 --> 0 | Active, not recruiting --> Withdrawn N=90 --> 0 | Active, not recruiting --> Withdrawn
- | Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: PIER: Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery (clinicaltrials.gov) - Jun 3, 2019
P2, N=47, Recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
N=90 --> 0 | Active, not recruiting --> Withdrawn Trial completion date: Oct 2020 --> Apr 2022 | Trial primary completion date: Oct 2020 --> Jan 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jun 2, 2019
P2, N=40, Recruiting, Sponsor: University of Rochester
Trial completion date: Oct 2020 --> Apr 2022 | Trial primary completion date: Oct 2020 --> Jan 2022 Not yet recruiting --> Recruiting | Trial completion date: Feb 2027 --> Jun 2027 | Initiation date: Feb 2019 --> May 2019 | Trial primary completion date: Feb 2022 --> Jun 2022
- |||||| pamrevlumab (FG-3019) / FibroGen
Enrollment open, Combination therapy, Metastases: LAPIS: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer (clinicaltrials.gov) - Jun 2, 2019
P3, N=256, Recruiting, Sponsor: FibroGen
Not yet recruiting --> Recruiting | Trial completion date: Feb 2027 --> Jun 2027 | Initiation date: Feb 2019 --> May 2019 | Trial primary completion date: Feb 2022 --> Jun 2022 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. (Pubmed Central) - May 31, 2019
Moreover, this effect was independent of T and N stage and histologic grade. These results suggest that obstruction should be incorporated into novel risk-stratification models.
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Review, Journal: Adjuvant treatment for pancreatic cancer. (Pubmed Central) - May 31, 2019
Further efforts are therefore to be made in early detection tools, the evaluation of neoadjuvant strategies, the development of new drug targets, and stratification strategies to better select patients for the available therapies. This review article summarizes the body of evidence on adjuvant treatment for pancreatic cancer, identifies evidence gaps and provides future perspectives.
- | Opdivo (nivolumab) / BMS
New P1/2 trial: Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - May 30, 2019
P1/2, N=36, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | Bylantra (devimistat) / Cornerstone Pharma
Trial completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 30, 2019
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
This review article summarizes the body of evidence on adjuvant treatment for pancreatic cancer, identifies evidence gaps and provides future perspectives. Trial completion date: May 2019 --> Aug 2019